Peer-influenced content. Sources you trust. No registration required. This is HCN.

Oncology Learning NetworkFDA Approves Tremelimumab Plus Durvalumab and Platinum-Based Chemotherapy for Metastatic NSCLC

This approval was based on findings from the open-label, randomized, multicenter POSEIDON trial, which compared data from two of the study’s three treatment arms. When compared to patients in the other treatment arm, patients in this group had a significantly improved OS, with a median OS of 14 months as opposed to 11.7 months.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form